image description

Tag: MD

Highlights from ACR Convergence 2024:  Groundbreaking LRA-Funded Research and Innovative Therapies

The Lupus Research Alliance (LRA) is proud to showcase the groundbreaking work of its funded researchers presented at the 2024 ACR Convergence meeting held this November in Washington, D.C. From novel steroid-sparing strategies to precision immunotherapies, this year’s presentations promise to bring new insights and transformative approaches to systemic lupus erythematosus (SLE) and related autoimmune […] Read More

Lupus Research Alliance Awards Lupus Insight Prize to Two Trailblazers in CAR T Cell Therapy

The Lupus Research Alliance (LRA) announced the recipients of the 2024 Lupus Insight Prize to Marko Radic, Ph.D., The University of Tennessee Health Science Center, and Georg Schett, M.D., Friedrich-Alexander-Universität Erlangen-Nürnberg, for their groundbreaking discoveries in utilizing CAR T cell therapy to potentially revolutionize lupus treatment. Drs. Radic and Schett were honored at a celebratory […] Read More

Recent Discoveries Shedding Light on Why Women Are at a Greater Risk for Lupus

Lupus is a complex autoimmune disease affecting millions worldwide with a staggering gender imbalance — about 9 of 10 people with lupus are women. Underlying biological, hormonal, or environmental factors likely contribute to why lupus affects females more often. Understanding why women are at greater risk for lupus could unlock novel treatments and revolutionize outcomes […] Read More

Overcoming the Uncertainties of Living with Chronic Diseases like Lupus

July 21, 2022 Interview with Michael D. Lockshin, MD, MACR Director Emeritus, Barbara Volcker Center for Women and Rheumatic Disease and Co-Director, Mary Kirkland Center for Lupus Research at Hospital for Special Surgery; Professor of Medicine and Obstetrics-Gynecology at Joan and Sanford Weill College of Medicine of Cornell University   Uncertainty and unpredictability are among […] Read More

Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca’s anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)

  First in New Class of Drugs in More than a Decade for SLE Targeting Type 1 Interferons NEW YORK, NY. August 2, 2021. The Lupus Research Alliance (LRA) is particularly excited about the U.S. Food and Drug Administration (FDA) approval of anifrolumab-fnia (Saphnelo™), a first-in-class type I interferon receptor antagonist indicated for adults with […] Read More

Less Risk and Greater Efficacy in Pediatric Lupus Nephritis Treatment

November 3, 2020 There is no doubt about it. The research into the mechanisms of pediatric lupus nephritis conducted by Elena Hsieh, MD, at the University of Colorado Anschutz Medical Campus, is driven by her genuine concern for the wellbeing of children—and a lifelong passion for science. With her new grant from the Lupus Research […] Read More

LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis

September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […] Read More

Watch Webcast Video: Redefining Lupus Trials Amid COVID-19 and Beyond

Videotape of 8.24.20 Learn from Lupus Zoom Webcast Ensuring the clinical trial process is accommodating for participants has always been the goal. However, COVID-19 has forced industry, research organizations, doctors, and patients to think twice about the process and its impact on high-risk populations including people with lupus who are immunocompromised. In light of COVID-19, […] Read More